Linagliptin/Metformin (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin is used in the treatment of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

• Type 2 diabetes mellitus (monotherapy): provides glycaemic control as initial oral therapy when diet and exercise are insufficient.
• Type 2 diabetes mellitus (combination therapy): added to other antidiabetic agents to achieve additional HbA1c reduction.
• Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise measures to improve overall glucose management.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP) and enhances glucose‑dependent insulin secretion while suppressing glucagon release. Metformin primarily reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, leading to decreased hepatic glucose output and increased glucose uptake in muscle. The fixed‑dose combination therefore addresses both insulin secretion and insulin resistance pathways in type 2 diabetes.

Linagliptin/Metformin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhoea: loose stools, often transient.
• Headache: mild cranial discomfort.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic complication, mainly linked to metformin.
• Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
• Severe hypersensitivity reactions: including skin rash, Stevens‑Johnson syndrome, or anaphylaxis.

When prescribing Linagliptin/Metformin, clinicians should observe several precautionary measures to minimise risk.

• Renal function assessment: evaluate eGFR before initiation and periodically thereafter.
• Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
• Hypoglycaemia monitoring: caution when combined with insulin or sulfonylureas.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Drug interaction review: assess concomitant medications that may affect metformin or linagliptin levels.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Linagliptin/Metformin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
• Iodinated contrast agents in patients with reduced renal function: can precipitate metformin‑associated lactic acidosis.
• Insulin or sulfonylureas: combined use raises risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics (thiazides): may reduce metformin clearance, requiring renal monitoring.
• ACE inhibitors or ARBs: may modestly increase risk of metformin‑related lactic acidosis.
• Beta‑blockers: can mask hypoglycaemic symptoms, necessitating patient education.